1. Introduction {#s0010}
===============

The paradigm of personalized medicine aims to provide the right treatment at the right dose for each patient. A global knowledge of the patient, including his/her way of life, comorbidities, medications, and pharmacogenotypes, is required to propose such personalized pharmacological treatment.

Certain lifestyle, social, and environmental factors have been suggested to promote systemic chronic inflammation, which can, in turn, lead to disease, such as cardiovascular disease ([@bb0315]), chronic infectious disease and cancer ([@bb0115]), diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease, and autoimmune and neurodegenerative disorders ([@bb0185]). In addition, people face acute infections or injury episodes throughout their life that are resolved by intermittent increases in inflammation. Yet, several papers have suggested that inflammation can modulate drug-metabolizing enzyme and transporter (DMET) activity ([@bb0490]; [@bb0675]). Therefore, a better knowledge of the impact of inflammation on DMETs and its related clinical consequences would help to understand inter and intraindividual variability of drug exposure and better manage drug exposure for each patient. Indeed, the clinical response to most drugs, *i.e.* efficacy or toxicity, is related to exposure to the drug or its active metabolites.

Several complementary pharmacological approaches have helped to ensure the most adapted drug exposure for each patient ([@bb0735]), but few have addressed inflammation as a major source of drug pharmacokinetic variability.

Pharmacogenetics allows the identification of genetic variants, the presence of which can strictly contraindicate the use of a drug (HLA-B\*5701 for abacavir) or contribute to explain interindividual pharmacokinetic or pharmacodynamic variability ([@bb0365]). Consequently, the determination of genotypes helps to predict a patient's phenotype and therefore to propose the right first dose of a drug when a treatment is initiated ([@bb0720]). However, a study performed on 114 Hungarian liver donors reported that the CYP2C19 phenotype was well-predicted by genotypic data in only 40% of patients ([@bb0340]). These data suggest that the prediction of metabolic capacity based on the determination of pharmacogenetic polymorphisms may be blunted by other determinants, including co-medication that interferes with DMETs or any inflammatory comorbidities that may have occurred during the lifetime of an individual ([@bb0675]).

Therapeutic drug monitoring makes it possible to verify the total exposure to narrow therapeutic index drugs. It is a useful approach to ensure the longitudinal pharmacological follow-up of patients with chronic treatment (*i.e.*, immunosuppressants, antipsychotics, antifungals) and adapt the dose for each patient whenever intrinsic or external changes occur. Liver or kidney function or co-medication with drugs that affect DMETs are well-known variables that can affect drug exposure. However, the influence of inflammation has received less attention.

Finally, pharmacokinetic models are useful tools to predict inter-dose plasma exposure to escalate or de-escalate the dose of a drug ([@bb0560]) during pharmacological follow-up. In addition to demographic information, these models consider classical features that contribute to inter- or intraindividual variability of drug exposure. However, the inflammatory status of the patient is rarely tested as a covariate, except for pharmacokinetic modelling of the exposure of biologics used for the treatment of inflammatory diseases.

Here, we present the contribution of inflammation to the modulation of DMET activity and discuss its related clinical consequences, beyond pharmacogenetics and drug/drug interactions. Finally, on behalf of the French Society of Pharmacology and Therapeutics, we provide opinions on how to integrate inflammation to personalize pharmacological treatment.

2. Roles of inflammation, kinetics, pivotal cytokines, and acute-phase proteins {#s0015}
===============================================================================

Inflammation is clinically defined as the presence of redness, swelling, and pain and results from a complex biological response to stimuli, such as pathogens, damaged cells, or irritants. It is a protective response, involving a wide range of host cells, blood vessels, proteins, and numerous mediators, aiming to eliminate the initial cause of cell injury, and necrotic cells to initiate the process of repair.

Inflammation can be classified as either acute or chronic. Acute inflammation, due to an infection for example, lasts a few days and is generally cleared by the immune system. Chronic inflammation is characterized by simultaneous destruction and healing of the tissue from the inflammatory process and the absence of any resolution of inflammation, giving rise to a host of diseases, such as cardiometabolic disease, autoimmune disease, or cancer ([@bb0520]).

Inflammation is induced when innate cells detect infection or tissue injury. The pattern-recognition receptors on immune cells sense "danger" from pathogen-associated molecular patterns (PAMPs) associated with pathogens or damage-associated molecular patterns (DAMPs) triggered by a wide range of host-derived endogenous stress signals. DAMPs are molecules, such as ATP, uric acid, and certain cytoplasmic and nuclear proteins that are released from damaged cells and contribute to sterile inflammation. Toll-like receptors (TLRs) are the major pattern-recognition receptors that are expressed on immune cells (monocytes, macrophages, neutrophils, and dendritic cells) and respond rapidly to the "danger" response. Bacterial and fungal nucleic acids are recognized by intracellular TLRs and other components by cell-surface TLRs. TLRs also recognize DAMPs ([@bb0305]).

Activated immune cells initiate the inflammatory process and are considered to be the most important source of various proinflammatory mediators, such as cytokines, chemokines, leukotrienes, or prostaglandins, which regulate acute-phase protein (APP) production. These systemic changes are referred to as "acute-phase responses", but they are produced under both acute and chronic inflammatory conditions.

Pro-inflammatory cytokines (mainly interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α)) and chemokines play a crucial role by recruiting additional immune cells to the site of infection for the phagocytosis and killing of pathogens. They can also activate nitric-oxide (NO) synthase 2 to produce NO in macrophages and hepatocytes ([@bb0510]).

Elevated pro-inflammatory cytokines are required to initiate acute inflammation and maintain chronic inflammatory responses. Their biological activity occurs at very low concentrations through binding to specific high-affinity TLRs on the cell surface, leading to activation of the transcriptional factor NF-κB ([@bb0710])**.**

IL-1β is a central mediator of innate immunity and inflammation. Its binding to functional TLRs induces the activation of NF-κB and MAPK (MAP kinases) signaling pathways, which leads to the transcription of genes encoding most inflammatory cytokines (IL-6 and TNF-α), chemokines, cyclooxygenase-2, and the inducible NO synthase. IL-6 binds with high affinity to cells expressing both membrane IL-6R and gp130. Hepatocytes express membrane IL-6R and gp130 and the liver is considered to be the main target organ of IL-6. TNF-α is expressed as a transmembrane protein but can be cut to release its soluble form, with higher biological activity. Targets for TNF-α include two type transmembrane receptors, TNF receptor I (TNFR-I or CD120a) and TNF receptor II (TNFR-II or CD120b).

The acute-phase reaction is a complex, highly-conserved innate response to infection or tissue damage. It involves the above-mentioned signals and a set of plasma proteins, called APPs, which are mainly released from hepatocytes in response to IL-6. Thus, the acute-phase reaction is associated with increased C-reactive protein (CRP), orosomucoid, serum amyloid protein A, complement C3, haptoglobin, and fibrinogen release and reduced production of albumin, transferrin, and fibronectin. The levels of APPs in serum correlate with the degree of inflammation ([@bb0035]; [@bb0190]). For example, in cultured hepatocytes, IL-6 induces a marked increase of CRP and serum amyloid protein A mRNA levels ([@bb0130]). Circulating levels of cytokines and APP are useful biomarkers to detect inflammation and measure its intensity in clinical practice. [Table 1](#t0005){ref-type="table"} summarizes the kinetics of APPs.Table 1Upregulated acute-phase proteins used as inflammatory biomarkers.Table 1Acute phase proteinMain roleNormal rangeTime after inflammatory stimulus (in hours)Maximum fold change in plasma concentrationCRP (C-reactive protein)Binding to pathogens and damaged cells, opsonin, complement activation\< 0.5 mg/L6-12 hx 1000PCT (procalcitonin)Unknown\< 10 pg/mL6- 8 hx 400-1000SAA (Serum amyloid A)Opsonin, regulation of innate defense, induction of extracellular matrix degrading enzymes, chemoattractant, apolipoprotein with HDL, regulation of lipid metabolism\< 10 mg/L6-12 hx 1000α1-glycoprotein (or orosomucoid)Binding of plasma proteins and mediators, chaperone, regulation of innate defense\< 1.5 g/L12 hx 2-4HaptoglobinScavenging of hemoglobin, antioxidants, angiogenesis, chaperone0.5-2 g/L12 hx 2-4FibrinogenClot formation2-4 g/L12 hx 2-4AAT (α1-anti trypsin)Enzyme inhibition2-4 g/L12 hx 2-4C3 complementPathogen recognition, destruction, chemotaxis, opsonin, vasoregulation0.8 à 18 g/L48 hx 1.5CeruloplasminIron and copper homeostasis0.2-0.6 g/L48 hx 1.5

As the acute inflammatory cascade develops to manage the "danger" signal, it is essential that controlled resolution begins, allowing immune homeostasis to return in an organized manner. At the peak of inflammation, anti-inflammatory cytokines, such as IL-10 and transforming growth factor-beta ([@bb0575]), as well as resolvins, lipoxins, and maresins initiate the resolution of inflammation.

3. Regulation of DMETs by inflammation {#s0020}
======================================

Preclinical models are useful tools to address the effect of infection-induced inflammation on drug metabolism in the absence of comorbidity. These models consist of injecting mice with lipopolysaccharide (LPS), a toxic component of Gram-negative bacterial cell walls, oral administration of enteropathogens, such as *Citrobacter rodentium* ([@bb0080]), or injection of parasites, such as *Schistosoma mansoni* ([@bb0460]) or *Plasmodium chabaudi* ([@bb0455]), to induce an inflammatory response. Indeed, these models all present an increase in proinflammatory cytokine transcription and release (see [Table 2](#t0010){ref-type="table"} ). Challenging primary culture hepatocytes with the major cytokines released during infection is another way to investigate the direct effect of inflammation on DMET expression and/or activity ([@bb0130]).Table 2Released cytokines and changes in liver mRNA/protein expression and activity of main cytochromes (CYP1A, 3A, 2B, 2C and 2D) and UGT1A in several experimental animal models of infection and chronic inflammation[a](#tf0005){ref-type="table-fn"}.Table 2Inflammatory stimulusAnimal speciesReleased cytokinesCYP1A3A2B2C9[b](#tf0010){ref-type="table-fn"}2C19[b](#tf0010){ref-type="table-fn"}2DUGT1AReferencesLipopolysaccharide129S1/svImJ mice*IL-1β, IL-6, TNF-αmRNAProteinActivity*Decreased - -Decreased Decreased -Decreased Decreased -Decreased Unchanged \-\--Decreased Decreased -([@bb0595]; [@bb0605])Lipopolysaccharide (\> 5 mg/kg bw)DBA-2 mice*TNF-α, IL-1β, IFNγ, IL-6, IL-17, IL-2, Il-10, IL-4mRNAProteinActivity*- - Decreased\-- - Decreased\-\-\--([@bb0125]; [@bb0500])*Citrobacter rodentium*C3H/HeOuJ mice*IL-1β, IL-6, TNF-αmRNAProteinActivity*Unchanged - -Decreased - Decreased-Decreased Decreased\--Decreased Decreased -([@bb0600]; [@bb0605])*Citrobacter rodentium*C57BL/6 mice*IL-6, TNF-α, IL-1βmRNAProteinActivity*Decreased - -Decreased Unchanged -Unchanged Decreased -Unchanged Decreased \--Increased Decreased \--([@bb0335])*Citrobacter rodentium*C57BL/6 mice*TNF-α, IL-6, IFN-γ, IL-10, IL-1βmRNAProteinActivity*Increased -Decreased Unchanged -Decreased - -Unchanged \--Unchanged-([@bb0540])*Citrobacter rodentium*C57BL/6 mice*IL-2, IL-6, IL-13, IFNβ, MCP-1, increasedIL-1β, IL-4, IL-5, IL-9,IL-10 unaffectedmRNAProteinActivity*Decreased - -Decreased Decreased -Decreased Decreased -Decreased Decreased \--Increased Increased \--([@bb0080])*Schistozomia mansoni* (45 days post infection)Swiss Webster mice*IL-4, IL-5, IL-13, IL-10, TGFβ1, TGFβ2, IL-1β, IL-6, IFNγ, TNF-αmRNAProteinActivity*Decreased Decreased -Decreased Decreased -Decreased DecreasedDecreased Decreased -Decreased Decreased -Decreased Decreased -Decreased - -([@bb0460])*Plasmodium chabaudi chabaudi*C57BL/6 mice*IL-1β, TNF-α, IFNγ, IL-6(mRNA)mRNAProteinActivity*Decreased - DecreasedDecreased Decreased Decreased- - DecreasedDecreased Decreased DecreasedDecreased Decreased DecreasedUnchanged Decreased DecreasedDecreased - -([@bb0455])Ovalbumin - multiple challengesICR mice-*mRNAProteinActivity*- Unchanged Decreased- Unchanged Decreased\-- Unchanged Decreased\-- Unchanged Decreased-([@bb0715])Human T-cell leukemia virus type I transgenic mice (rheumatoid arthritis model)BALB/c mice*IL-1β, IL-6TNF-α unaffectedmRNAProteinActivity*-Decreased Decreased Decreased-Unchanged - \-\-\--([@bb0020])Collagen antibody induced arthritisBALB/c mice*IL-1β, IL-6, SAAIL-2, TNF-α unaffectedmRNAProteinActivity*Decreased - DecreasedDecreased - DecreasedDecreased - DecreasedDecreased - Decreased-+/- - UnchangedDecreased - -([@bb0130])*Mycobacterium tuberculosis* (adjuvant arthritis model)Lewis rats*TNF-α, IL-1β, IL-1α, IL-6mRNAProteinActivity*-Decreased Decreased DecreasedDecreased Decreased Decreased\-\-\--([@bb0640])Trinitrobenzene sulfonic acid-induced colitis (model of inflammatory bowel disease)Wistar rats*IL-6mRNAProteinActivity*- Unchanged Decreased- Decreased Decreased\-- Decreased Decreased\--([@bb0435])*Citrobacter Rodentium* (model of inflammatory bowel disease)C57BL/6 mice*IL-2, IL-6, TNF-α, KC, IFNγ, MIP1α, MCP-1, RANTESmRNAProteinActivity*Decreased Decreased -Decreased Decreased -Decreased Decreased -Decreased Decreased \--Increased Increased \--([@bb0085])*Mycobacterium butyricum* (adjuvant arthritis model)Sprague-Dawley rats*TNF-αmRNAProteinActivity*- Decreased Decreased- Decreased Decreased\-\-\-\--([@bb0400])diabetesZucker fatty rat*-mRNAProteinActivity*Unchanged Unchanged UnchangedDecreased Decreased DecreasedDecreased Decreased DecreasedUnchanged Unchanged UnchangedDecreased Decreased Decreased\--([@bb0815])Streptozotocin-induced diabetes mellitusSprague-Dawley rats*-mRNAProteinActivity*- Increased \-- Increased Increased- Increased \-\-- Decreased \-- Increased \--([@bb0230])Engelbreth-Holm-Swarm sarcoma (model of extra-hepatic cancer)C57BL/6 mice*IL-6mRNAProteinActivity*-Decreased - Decreased\-\-\-\--([@bb0300])High fat dietSprague-Dawley rats*-mRNAProteinActivity*Decreased Decreased Decreased+/- +/- UnchangedDecreased - Decreased-Decreased Decreased DecreasedUnchanged - UnchangedDecreased - Decreased([@bb0835])[^2][^3][^4]

Other pre-clinical models mimic certain chronic inflammatory diseases, including colitis ([@bb0080]; [@bb0435]), arthritis ([@bb0020]; [@bb0130]; [@bb0640]), diabetes ([@bb0205]; [@bb0795]; [@bb0825]), or extrahepatic cancer ([@bb0300]). Most studies have reported reduced expression of the main DMETs, notably members of the CYP 1A, 3A, 2B and 2C superfamilies, and, to a lesser extent, UDP-GT, as well as ATP-binding cassette (ABC) and solute carrier (SLC) transporters ([@bb0795]).

Overall, three major mechanisms have been proposed to explain the downregulation of inflammation on DMET expression and activity.

3.1. Inflammation induces transcriptional inhibition of many DMETs {#s0025}
------------------------------------------------------------------

Most studies using LPS as a trigger of inflammation have reported decreased mRNA and protein levels and reduced activity of certain hepatic CYPs commonly involved in drug metabolism, either at baseline (see [Table 2](#t0010){ref-type="table"}) or in response to challenge with pregnenolone-16a-carbonile, an agonist of the pregnane X receptor (PXR) ([@bb0500]). For example, reduction of CYP3A11 mRNA levels was associated with decreased clearance of its substrates, nifedipine and testosterone ([@bb0500]). CYP suppression occurred between 7 and 10 days post-oral inoculation of *Citrobacter rodentium* in mice ([@bb0080]). Such kinetics of CYP down-regulation are consistent with a transcriptional inhibitory mechanism.

Similarly, mice infected with parasites (*Schistosoma mansoni* or *Plasmodium chabaudi*) (see [Table 2](#t0010){ref-type="table"}) show CYP down-regulation. Again, reduced CYP and UDP-GT expression at the transcriptional and protein levels in infected mice are associated with increased exposure to nifedipine, caffeine, bupropion, tolbutamide, and midazolam ([@bb0455]).

These findings all show that infection by bacteria or parasites may inhibit CYP transcription and expression, which translates into reduced CYP activity. The inhibition of liver microsomal CYP1A2 and CYP2B5 expression and activity occurs only at concentrations of LPS that promote an increase in the level of serum inflammatory cytokines and NO ([@bb0125]), suggesting that pro-inflammatory cytokines and NO may be intermediate molecular links between inflammation and CYP downregulation ([@bb0675]). Moreover, deletion of the gene encoding IL-6 prevented the down-regulation of CYP2D and CYP3A in *Clostridium rodentium*-infected mice, whereas the down-regulation of CYP4A remained unchanged ([@bb0545]). Furthermore, deletion of the gene encoding IFN-γ prevented the LPS-induced down-regulation of CYP2D, whereas it did not affect the inhibition of CYP3A and CYP4A in the same experimental model ([@bb0545]). These findings show heterogeneous effects of cytokines on CYP expression and activity, with differences in magnitude, potency ([@bb0135]), and time-course, depending on the administered infectious agent (see [Table 2](#t0010){ref-type="table"}).

Similar downregulation of DMETs in preclinical models of certain chronic inflammatory diseases has been recently reviewed ([@bb0795]). Various models of colitis ([@bb0080]; [@bb0435]) and arthritis ([@bb0020]; [@bb0130]; [@bb0640]) show diminished hepatic expression and/or activity of many CYP450 enzymes (CYP3A, 4A, 2C, 1A2, and 2E1). Such down-regulation appears to correlate with an increase in pro-inflammatory cytokine concentrations (IL-6 and TNF-α, as well as IFN-γ, IL-2, IL-1α, and IL-1β) ([@bb0080]; [@bb0435]; [@bb0640]) and could explain the increased concentrations of propranolol ([@bb0225]) and verapamil ([@bb0400]) observed in adjuvant-induced arthritis.

IL-6 is one of the most abundant cytokines released in the plasma of infected mice ([@bb0080]). IL-6 represses CYP3A4 expression ([@bb0810]) and decreases CYP3A-dependent clearance in a dose-dependent manner in human hepatocyte cells in culture ([@bb0135]). Moreover, pretreatment of human hepatocytes with an IL-6 monoclonal antibody inhibited the decrease in IL-6-induced CYP3A clearance ([@bb0135]), providing definitive proof for the contribution of IL-6 in reducing CYP3A-dependent clearance. However, the inhibitory effect of IL-6 is not limited to CYP3A, as a large panel of CYPs was also shown to be down-regulated in murine models of infection ([Table 2](#t0010){ref-type="table"}), a genetic murine model of arthritis ([@bb0020]), and cultured hepatocytes ([@bb0005]).

Similar experiments have also suggested a major role of TNF-⍺ in CYP downregulation, as deletion of the gene encoding the TNF-⍺ receptor ([@bb0335]) or treatment with a biologic drug that neutralizes soluble TNF-⍺ ([@bb0540]) prevented the downregulation of CYP3A11 and CYP3A25 in *Citrobacter rodentium*-infected mice. Infliximab treatment of pre-adjuvant arthritic rats resulted in significantly higher total CYP protein content than that in untreated pre-adjuvant arthritic rats ([@bb0405]). These data, along with those from *in vitro* hepatocyte experiments showing that TNF-⍺ powerfully regulates CYP levels ([@bb0335]; [@bb0545]), provide strong evidence for the role of TNF-⍺ in CYP downregulation.

Conversely, several studies reported induction of certain CYPs: CYP2D9 in rodents models of infectious colitis ([@bb0080]; [@bb0085]) or diabetes ([@bb0230]) (see [Table 2](#t0010){ref-type="table"}), CYP3A13 in mice with collagen antibody-induced arthritis ([@bb0130]) or oral infection by *Citrobacter rodentium* ([@bb0600]), CYP4A and CYP2E subfamilies in LPS-treated F344 rats ([@bb0485]). Experimental studies performed in various rodent models of diabetes ([@bb0795]) have also provided conflicting results in terms of expression of DMETs, with expression and activity either increased ([@bb0825]) or decreased ([@bb0205]). All these discordant results could be related to the differences in rodent species (rat vs mice) and strains (Sprague-Dawley rats vs Zucker diabetic fatty rat for example), and inflammatory stimuli that were used (injection of LPS, chemical irritant or infectious agent) in different experimental conditions (see [Table 2](#t0010){ref-type="table"} and the review of Morgan et al ([@bb0485])).

The effect of inflammation on other enzymes involved in drug metabolism and on transporters has received less attention. Infection by *Citrobacter rodentium* ([@bb0335]) or *Plasmodium chabaudi* ([@bb0455]) significantly reduces hepatic flavin monooxygenase mRNA levels. Infection by *Plasmodium chabaudi* ([@bb0455]) or *Clostridium rodentium* or treatment with LPS ([@bb0605]) significantly downregulated several genes encoding the hepatic UDP-GT1A1, 1A9, and several of those of the UGT2B subfamily, an effect associated with the reduced expression of UDP-GT1A1 and UDP-GT2B protein. Again, the effect of inflammation on UDP-GT regulation appears to be cytokine-dependent and UDP-GT isoform specific, as also reported for CYP. However, IL-6 downregulates most phase 2 enzymes involved in drug metabolism in human primary hepatocytes ([@bb0310]).

An *in vitro* study on human liver microsomes suggested that certain nonsteroidal anti-inflammatory drugs may have an inhibitory potential on UDP-GT isoforms, suggesting that certain mediators of the cyclooxygenase-dependent pathway may be involved in the regulation of DMET activity. However, the underlying mechanism and the clinical relevance in terms of UDP-GT substrate clearance need to be further investigated ([@bb0295]).

The hepatic transporters involved in drug clearance belong to two gene families, ATP-binding cassette (ABC) and SLC. Significant down-regulation of hepatic mRNA levels of SLC22a4, SLCOa4, and SLCO2b1, as well of ABCb1, ABCg2, has been reported in *Citrobacter rodentium*-infected mice relative to controls ([@bb0450]). This effect was blocked in infected mice lacking IL-6 or TNF⍺ ([@bb0450]), again suggesting a key role of these cytokines in the downregulation of certain SCL and ABC transporters. A study on primary human hepatocytes challenged with IL-6 has extended these findings to numerous transporters of the ABC and SLC families ([@bb0310]).

The binding of pro-inflammatory cytokines to their specific receptors leads to the activation of several transcription factors, including NF-κB. The direct binding of NF-κB to DMET promoter regions inhibits the heterodimerization of nuclear retinoid x receptor (RXR)-α to constitutive androstane/active receptor (CAR), pregnane X receptor (PXR), and peroxisome proliferator activation receptor (PPAR) nuclear receptors. Yet, the heterodimerization of RXR to other nuclear receptors plays a central role in the regulation of genes encoding DMETs ([@bb0310]; [@bb0795]). Moreover, inflammation related to *Plasmodium chabaudi* is associated with the downregulation of CAR and farnesoid X receptor (FXR) and, to a lesser extent, PXR and RXR mRNA ([@bb0455]). Thus, within the complex network that links transcriptional factors with the expression of DMET, NF-κB pathway activation by pro-inflammatory cytokines contributes to the inhibition of DMET transcription observed during inflammation ([@bb0310]).

3.2. Inflammation induces NO-dependent proteasome degradation of DMETs {#s0030}
----------------------------------------------------------------------

Several studies have suggested that post-transcriptional mechanisms may also modulate CYP activity. A chronic allergic murine model induced by repeated administration of ovalbumin showed down-regulation of CYP 1A2, CYP2C, 2E1, and CYP3A activity, although CYP protein expression remained unchanged relative to that of control animals ([@bb0715]). IL-1β challenge in cultured rat hepatocytes decreased CYP3A1 protein expression by 40% and reduced its activity within 6 h ([@bb0370]). Such rapid kinetics suggest that post-transcriptional mechanisms may be involved in the early downregulation of CYP3A1. Several studies have reported that early cytokine-mediated downregulation of CYP is inhibited by a NO synthase inhibitor ([@bb0070]) or proteasome inhibitor ([@bb0370]; [@bb0490]). Similarly, effective inhibition of NO synthase reduced the hydrolase activity of several CYP enzymes but did not impair the downregulation of CYP2C29 or CYP3A11 mRNA expression or CYP2C, CYP2E, or CYP34 protein expression in rats treated with LPS ([@bb0670]). Finally, native CYP2B6 protein was rapidly downregulated in HeLa cells within 3 h of treatment with a NO donor, whereas the level of its mRNA was not ([@bb0380]). These data all suggest that NO and proteasome-dependent pathways are likely to be involved in the early phase of CYP protein downregulation. Activation of the inducible NO synthase ([@bb0455]) promoted by IL-1β, IFN-γ, and TNF-⍺ during the inflammatory response leads to increased NO synthesis and release, which in turn reduces CYP activity through reversible binding to the heme moiety or tyrosine and cysteine S-nitrosilation or nitration. In addition, NO induces proteasome-dependent CYP3A4 inhibition, as a proteasome inhibitor blocks IL-1β and NO-induced downregulation of CYP3A4 ([@bb0370]). Given that IL-1β is a cytokine synthesized during the initial phase of the inflammatory response, these data all suggest that the functional inhibition of CYP activity occurs early in the inflammatory process.

3.3. Inflammation induces epigenetic modifications of DMET genes {#s0035}
----------------------------------------------------------------

Epigenetic changes regulate the expression and activity of genes involved in DMETs, as recently reviewed ([@bb0365]), and contribute to interindividual differences in drug responses ([@bb0275]). The level of DNA methylation in the promoters of several CYPs (CYP3A4, CYP1A2, CYP2C19 and UDP-GT1A4) inversely correlates with their levels of expression in adult liver ([@bb0240]). Similarly, the modification of histone patterns inversely correlates with the level of expression of several drug transporters (ABCb1, ABCg2) in prostate carcinoma ([@bb0265]). Consequences on DMET expression or activity are expected, as inflammation itself also induces epigenetic regulation of the innate immune response ([@bb0840]) and triggers the release of certain miRNAs from immune cells ([@bb0360]). Indeed, methylation levels at the CYP11A1 locus significantly correlate with CRP levels in the serum of patients with bipolar mania, suggesting an association between inflammation and epigenetic changes of CYP ([@bb0635]). Furthermore, miRNAs have been reported to contribute to the variability of CYP, including reduced expression and activity of CYP2C9, CYP2C8, CYP2C19 ([@bb0610]), CYP2D6 ([@bb0830]) and CYP3A4 ([@bb0360]). A recent study evidenced upregulation of several miRNAs in livers from donors with elevated CRP concentrations compared to those with a normal concentration ([@bb0360]). Some of these miRNAs were able to attenuate DMET expression and activities or to target nuclear receptors to block gene transcription, CYP2C19 and CYP3A4 being the top downregulated.

In summary (see [Fig. 1](#f0005){ref-type="fig"} ), these data all suggest that acute or chronic inflammation can inhibit the level and activity of major CYPs and, to a lesser extent, type 2 enzymes and ABC and SLC transporters involved in drug pharmacokinetics. These inhibitory effects may occur both in the intestine ([@bb0680]) and liver, leading to impaired absorption and pre-systemic and hepatic metabolic phenoconversion. In acute inflammation, phenoconversion would result in a shift towards poorer metabolizing phenotype, providing there are no other cause of inhibition. In chronic inflammation, treatment with a drug that inhibits the inflammatory pathway (i.e. IL-6 monoclonal antibody) might revert the phenotype to its physiological status, providing there is no other cause of induction. Thus, inflammation can contribute to the intra and interindividual variability of drug responses.Fig. 1Scheme of the inhibitory influence of inflammation on drug-metabolizing enzyme and transporter (DMET) activity, leading to overexposure to drugs that are DMET substrates and have a narrow therapeutic index. Pathogen-associated molecular patterns or damage-associated molecular patterns stimulate pro-inflammatory cytokine pathways, leading to transcriptional and post-transcriptional changes in DMETs. Transcriptional mechanisms involve NF-κB activation, which inhibits the heterodimerization of nuclear retinoid x receptor (RXR)-α to other constitutive nuclear receptors (NR) (1), thus inhibiting DMET transcription (2) (under the magnifying glass). Non transcriptional mechanisms involve the direct inhibition of DMET by NO and the induction of proteasome-dependent CYP3A4 inhibition by NO. Finally, epigenetic changes, such as DNA methylation in response to inflammation, contribute to reduced DMET activity (under the magnifying glass).NR: nuclear receptor, including the peroxisome proliferator activating receptor, pregnane X receptor, retinoid X receptor-α, and constitutive androstane receptor.Solid lines indicate activation and dotted lines indicate inhibition.Fig. 1

4. Pharmacological consequences of acute inflammation-induced metabolic phenoconversion in patients with acute inflammation {#s0040}
===========================================================================================================================

Approximately 80% of all drugs are primarily metabolized by CYP isoforms, notably CYP1A2, 2D6, 3A4, 2C9, and 2C19. As a consequence, inflammation could theoretically influence their pharmacokinetics. This point is of high clinical relevance for drugs with a narrow therapeutic index, which are candidates for TDM. [Table 3](#t0015){ref-type="table"} presents the effect of inflammation on the blood or plasma exposure and/or pharmacokinetic parameters of the main drugs for which TDM is routinely performed.Table 3Studies evaluating the impact of acute inflammatory episodes on the pharmacokinetics of drugs that are candidates for therapeutic drug monitoringTable 3Pharmacological class and drugMains enzyme (transporter) involvedStudy typePatients number (plasma/blood samples)Population study (country)Duration of the phenoconversionConcentration of inflammatory biomarkersPharmacokinetic consequencesClinical consequencesReferencesAntipsychoticsclozapineCYP1A2prospective observational study\
14 (70)Schizophrenic patients with influenza vaccination\
(Finland)naNo difference in CRP after vaccinationNo difference in \[clozapine\] and \[metabolites\] after vaccination.na([@bb0585])clozapineCYP1A2retrospective comparative study63 (63) (36 with therapeutic \[clozapine\]\* and\
27 with \[clozapine\] \> 800 ng/mL)Heterogeneous psychiatric patients\
(Germany)naCRP: 0.69 ±1.42 mg/L (therapeutic \[clozapine\]); 3.64 ± 6.13 mg/L (\[clozapine\] \> 800 ng/mL)Higher frequencies of increased CRP (\> 5 mg/L) in patient with elevated \[clozapine\]na([@bb0565])clozapineCYP1A2retrospective comparative study33 (116): CRP ≥ 5 mg/LHeterogeneous psychiatric patients\
(Germany)naCRP: 19.0 \[range: 5.1-242.0\] (≥ 5 mg/L group); 3.5 \[range: 0.5-4.7\] mg/L\
(\< 5 mg/L group)Increased C/D and decreased norclozapine/clozapine metabolic ratio in patients with CRP ≥ 5 mg/Lna([@bb0255])clozapineCYP1A2retrospective observational study16 corresponding to 18 episodes of inflammation\
/infection (46)Schizophrenic patients with inflammation\
/infection\
(China)nanaIncreased C/D in 16/18 episodes.\
Reducing the clozapine dose to the half would be advisable in 11 episodes and to one-third in 5 episodes.na([@bb0620])clozapineCYP1A2case report2Schizoaffective disorder patient with dermatitis and pulmonary infection\
(China)about 4-5 daysnaIncreased C/D, \[clozapine\] and \[norclozapine\] during infectionna([@bb0625])clozapineCYP1A2case report4Psychiatric patients\
(Netherlands)naCRP:\
116 mg/L\
na\
na\
na\[clozapine\]\* (dose):\
1012 ng/ml (600 mg)\
1824 ng/mL (400 mg)\
2349 ng/mL (500 mg)\
915 ng/mL (500 mg)Clinical deterioration, loss of appetite, vomiting, somnolence([@bb0235])clozapineCYP1A2case report1Adult schizophrenic with severe respiratory infection\
(USA)nana\[clozapine\]\* (dose):\
1245 ng/mL (600 mg)Sedation and problems walking([@bb0390])clozapineCYP1A2case report1Adult with maniac and paranoid syndrome and urinary infection\
(Germany)naCRP at day 13: 81.5 mg/L\[clozapine\]\* (dose) at day 17:\
1006 ng/mL (200 mg)na([@bb0280])clozapineCYP1A2case report1Adult with schizophrenia, Crohn disease and admitted for a suspected gastrointestinal infectionnaCRP at admission: 130 mg/L\[clozapine\]\* (dose)\
- 1 month before admission: 627.1 ng/mL (900 mg)\
- At admission: 2965.4 ng/ml (900mg)na([@bb0160])risperidoneCYP2D6\
case report2Adult psychiatric patients (Germany)about 2 daysCRP range: 0.8 to 110.0 mg/LSimultaneous evolution of CRP and C/D during the follow-up of 16 and 5 daysna([@bb0245])risperidoneCYP2D6\
retrospective comparative study32 (102): CRP \> 5 mg/LHeterogeneous psychiatric patients\
(Germany)naCRP: 11.0 \[range: 5.6-110.0\] (\> 5 mg/L group);\
2.7 \[range: 0.0-4.8\] mg/L (\< 5 mg/L group)Increased risperidone +OH-risperidone C/D in patients with CRP ≥ 5 mg/L\
No difference in risperidone/OH-risperidone metabolic ratio between 2 groupsna([@bb0255])risperidoneCYP2D6case report156-year-old men with schizophrenia and atypical pneumonianaCRP : 30.0 mg/LIncreased risperidone + OH-risperidone concentration to 405 nmol/L 1 week after admission (therapeutic range 50-140 nmol/L).no adverse effect was observed([@bb0260])quetiapineCYP3A4\
retrospective comparative study40 (101): CRP \> 5 mg/LHeterogeneous Psychiatric patients\
(Germany)naCRP: 1.5 \[range : 5.3-116.0\] (\> 5 mg/L group):\
2.8 \[range : 0.2-4.5\] mg/L (\< 5 mg/L group)No difference in norquetiapine/quetiapine metabolic ratio or quetiapine C/D between the 2 groupsna([@bb0255])  AntidepressantscitalopramCYP2C19retrospective comparative study30 (30) (15 with CRP \> 5 mg/L and 15 with CRP \< 5mg/L)Heterogeneous psychiatric patients\
(Germany)naCRP: 13 \[range :5.2-37.0\] (\> 5 mg/L group); 2.0 \[range :0.5-4.7\] mg/L\
(\< 5 mg/L group)No difference in C/D and metabolic ratio between the 2 groupsna([@bb0250])venlafaxineCYP2C19\
CYP2D6\
retrospective comparative study78 (78) (39 with CRP \> 5 mg/L and 39 with CRP \< 5mg/L)Heterogeneous psychiatric patients\
(Germany)naIn CRP: 11 \[range: 5.3-232.0\] (\> 5 mg/L group); 3.2 \[range: 0.0-4.8 mg/L\] mg/L (\< 5 mg/L)No difference in C/D and metabolic ratio between the 2 groupsna([@bb0255])  AntiepilepticsperampanelCYP3A4retrospective comparative study111 (111) (23 with CRP \> 15 mg/L and 88 with CRP \<15mg/L)Heterogeneous epileptic patients\
(Japan)C/D ratio returned to baseline within 1 week after normalization of CRP (case presentation of one pediatric patient)In CRP \> 15 mg/L group: 42 mg/L \[range : 15-102 mg/L\]\
Increased C/D ratio in patients with CRP \> 15 mg/L both in the presence and absence of comedication with enzyme-inducing antiepilepticsNo adverse events were recorded([@bb0805])clobazamCYP3A4case report1Child with Rett syndrome and pneumonia (Japan)nanaNo change in \[clobazam\] or\
\[N-desmethylclobazam\] during the study period of 77 daysNo adverse events were observed([@bb0805])  Sedative drugsmidazolamCYP3A4\
external evaluation of a previously developed PK model ([@bb0760])136 (1045)Neonates, infants, children and adults\
(Netherlands)naCRP: 0.1 to 341 mg/LMPE \<30% for predicted CL in postoperative or critically ill patients and term neonates, critically ill and healthy adults.\
MPE \> 180% in preterm neonatesna([@bb0055])midazolamCYP3A4\
prospective observational study\
(PK analysis)83 (523)Critically ill children\
(Netherlands)naIn simulations, CRP of 300 mg/L was associated with 65% lower clearance compared to 10 mg/LAssociation between CL and:\
- CRP\
- organ failure\
No association between CL and IL-6 and TNFα levelsna([@bb0760])midazolamCYP3A4\
prospective observational study\
(PK analysis)45 (192)Terminally ill adult patients (Netherlands, 91.1% Caucasian)naCRP: 92 \[range: 1-625\] mg/LCorrelation between CL and albumin or CRP (depending on the order on the backwards elimination in covariates selection)na([@bb0175])midazolamCYP3A4\
prospective observational study\
(PK analysis)21 (na)Critically ill children\
(Netherlands)nanaNo association between CL and inflammatory markers (CRP and leucocytes count).\
Correlation between CL and disease severityna([@bb0765])  Immunosuppressant drugs (mTOR inhibitor)sirolimusCYP3A4/5\
(Pgp)prospective observational study (PK analysis)52 (676)Children with vascular anomalies\
(USA)nanaDrop of about 50% of CL during documented infectionna([@bb0465])sirolimusCYP3A4/5\
(Pgp)Case report2Children with acute lymphoblastic leukemia (USA)At least 2 daysnaHigh Cmin when patients had flu-like symptoms (fever and cough)Toxicity events (seizure and mouth sore)([@bb0470])  Immunosuppressant drugs (antiproliferative drug)mycophenolate sodium (enteric-coated)UGT1A8/9prospective observational study (PK analysis)66 (666)Kidney transplant adults (Germany)nanaHigher AUC~0--12h~ in patients with recurrent infections compared to patients without infectionsna([@bb0690])mycophenolate mofetilUGT1A8/9prospective observational study\
(PK analysis)46 (127)(15 with infection or gastrointestinal disease and 31 without)Kidney transplant adults (Japan)nanaA trend towards higher AUC~0-9h~ in patients with infection or gastrointestinal disease compared to those withoutna([@bb0555])  Immunosuppressant drugs (calcineurin inhibitor)tacrolimusCYP3A4/5\
(Pgp)prospective observational study (PK analysis)30 (200) (11 with diarrhea and\
9 controls)Kidney transplant adult (Belgium)nanaAssociation between diarrhea and Cmin\
Increase of C/D between 90 and 360 min after intake.\
No change of Tmax and t1/2 Decrease by about 50% (± 50%) of intestinal Pgp activity during diarrheana([@bb0385])tacrolimusCYP3A4/5\
(Pgp)prospective observational study (PK analysis)20 (na)Kidney transplant adults (Japan)from 2 to 4 weeksnaHigher Cmin, AUC, and Cmax during episodes of diarrheana([@bb0650])tacrolimusCYP3A4/5\
(Pgp)case report2 (23)Liver transplant adults (Japan)from 2 to 4 weeksnaDecrease of Cmin two weeks after 2 or 4 weeks of direct-acting antivirals administration for HCV infectionDose increase adjustment between 25% and 50 %([@bb0685])tacrolimusCYP3A4/5\
(Pgp)case report1 (13)Liver transplant child (Japan)nanaIncrease of Cmin by 100% after an episode of diarrhea with feverna([@bb0410])tacrolimusCYP3A4/5\
(Pgp)case report2 (7)Liver transplant\
adultsnaCRP range: 70 to 236 mg/LIncrease of Cmin\
Increase of C/D by 92 to 141% after inflammatory eventsna([@bb0040])cyclosporineCYP3A4/5\
(Pgp)retrospective observational study6 (88)Adult recipients of allogeneic stem cell transplant (France)naPeak IL-6 : 212.2 ± 56.8 UI/ml\
Peak CRP: 179.2 ± 12.5 mg/L\
Peak α1-acid glycoprotein : 2.59 ± 0.32 gm/LCorrelation between time of IL-6 peak and:\
-three-fold increase in blood \[cyclosporine\]\
-twofold increase in \[AM1\*\*\]Cyclosporine dose decrease between 25 and 50%([@bb0100])cyclosporineCYP3A4/5\
(Pgp)case report1 (10)Liver transplant adult (Japan)nanaIncrease of Cmin by 300%\
24 hours after an episode of diarrhea with feverna([@bb0410])  Triazole antifungalsvoriconazoleCYP2C19, CYP3A4prospective observational study34 (489)Adult hematological and SOT patients\
(Netherlands)naNaIncrease of Cmin by 1.005321^N^ and decrease of \[voriconazole-N-oxide\] by 0.99775^N^, with N being the difference in CRP units (expressed in mg/L)na([@bb0755])voriconazoleCYP2C19, CYP3A4prospective observational study22 (143)Hematological adult\
(Netherlands)naCRP: 37 \[12 - 75\] mg/L\
IFNɣ: 15 \[10-29\] pg/mL\
IL10: 35 \[12-66\] pg/mL\
IL1-RA: 34 \[18-106\] pg/mL\
IL1ß: 9.5 \[8.5--11\] pg/mL\
IL6: 32 \[12-80\] pg/mL\
IL8: 54 \[22-122\] pg/mL\
TNFα: 26 \[15-44\] pg/mLIndependent association between Cmin and CRP, IL-6, and IL-8.\
Absence of association between Cmin and other cytokinesna([@bb0770])voriconazoleCYP2C19, CYP3A4retrospective observational study67 (520)Adult recipients of allogeneic stem cell transplant\
(Japan)naCRP: 32 \[range: 1--200.1\] mg/LCRP ⩾ 4 mg/L identified as an independent factor of Cmin ⩾1 mg/Lna([@bb0820])voriconazoleCYP2C19, CYP3A4retrospective observational study29 (260)Adult recipients of allogeneic stem cell transplant\
(France)naCRP: 8 \[3-24\] mg/LIndependent positive association between Cmin and CRP\
Increase of 24% of Cmin for each 1-log decimal increase of CRPna([@bb0195])voriconazoleCYP2C19, CYP3A4retrospective observational study113 (250)Hematological adult\
(China)naCRP: 5.99 (range:3-171) mg/L\
IL1ß: 0.03 (\< 0.1-489.3) pg/mL\
IL6: 135.1 (1.98-2969.1) pg/mL\
IL18: 141.9 (5.7-1834.7) pg/mL\
TGFß1: 1750.9 (37.5-37916) pg/mL\
IFNɣ: 0.23 (\< 0.3-24.5) pg/mLAbsence of association between Cmin and CRP\
Association between Cmin and:\
-IL-18 in patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia-TGFß1 in acute myeloid leukemiaIndependent negative association between IL-6 and Cminna([@bb0415])voriconazoleCYP2C19, CYP3A4retrospective observational study50 (139)Adult hematological and SOT patients\
(Netherlands)naCRP:67 \[14-153\] mg/LAssociation between Cmin and CRP\
Simultaneous evolution of Cmin and CRP level at individual levelna([@bb0155])voriconazoleCYP2C19, CYP3A4retrospective observational study128 (128)Adult hematological and SOT patients\
(Netherlands)naCRP: 71 \[15--152\] mg/LIndependent positive association between CRP and Cmin\
For every 1-mg/L increase in the CRP, increase of 0.015 (CI 95%: 0.011-0.020) mg/L of Cmin.\
Simultaneous evolution of Cmin and CRP at individual levelna([@bb0740])voriconazoleCYP2C19, CYP3A4retrospective observational study19 (101)Adult hematological and SOT patients\
(Netherlands)naCRP: 76.6 (range: 5.0--279.0) mg/LCorrelation between CRP and:\
- Cmin\
- metabolic ratio\
Increase of 0.021 mg/L for Cmin for each increase of 1 mg/L of CRPna([@bb0150])voriconazoleCYP2C19, CYP3A4retrospective observational study63 (77)Adult hematological and SOT patients\
(Japan)naCRP: 5.6 ±6.4 mg/LIncreased CRP identified as an independent predictor of C/Dna([@bb0145])voriconazoleCYP2C19, CYP3A4retrospective observational study65 (72)na\
(Japan)nanaIndependent association between CRP and:\
- first Cmin\
- metabolic rationa([@bb0530])voriconazoleCYP2C19, CYP3A4retrospective observational study41 (41)Heterogeneous immunocompromised patients (Japan)naCRP: 3.46 \[1.36--7.57\] mg/LCorrelation between CRP :\
- Cmin/D\
- metabolic rationa([@bb0505])voriconazoleCYP2C19, CYP3A4case-control study62 (62) (31 cases with Cmin ≥ 4 mg/L\*\* and 31 controls)Hematological adults\
(France)naCRP:188 \[109--227.5\] (case); 37 \[13.2--83.0\] mg/L (control)Class of CRP (\> 96mg/L) identified as the unique independent factor of overexposure\*\*na([@bb0200])voriconazoleCYP2C19 CYP3A4\
FMO3retrospective comparative study27 children (11 \< 12 years and 16 \> 12 years)Na\
(Netherlands)nanaPositive association between CRP and Cmin in child \>12 years\
No association between CRP and Cmin in children \< 12 yearsna([@bb0025])voriconazoleCYP2C19, CYP3A4case report1 (11)Hematological adult\
(France)naCRP range: 25 to 263 mg/LSimultaneous evolution of CRP and Cmin during the follow-up of 60 daysna([@bb0730])posaconazoleUGT1A4prospective observational study55 (511)Hematological adult\
(Netherlands)naCRP: 23.5 \[5-75\] mg/LNo association between CRP and Cminna([@bb0430])itraconazoleCYP3A4/5retrospective observational study42 (42)Heterogeneous immunocompromised patients (Japan)naCRP: 0.12 \[0.04--0.66\] mg/LNo association between CRP and:\
- C/D\
- hydroxyitraconazole\
- metabolic rationa([@bb0505])Anti-asthmatic drugstheophyllineCYP1A2retrospective comparative study52 (na)Children with asthma (Japan)about 2 daysnaIncreased incidence of CRP \> 0.5mg/L or fever in patients with lower Cmin72 h/Cmin24 h compared to patients with higher Cmin72 h/Cmin24 h rationa([@bb0800])theophyllineCYP1A2case report11 (na)Children with asthma\
(USA)between 1 to 3 monthsnaIncreased Cmin during influenza infectiontoxic symptoms (seizure, nausea/vomiting, headache) in 10/11 patients([@bb0350])theophyllineCYP1A2case report5 (na)Children with asthma (USA)nandIncreased t1/2 during acute viral infectionna([@bb0090])theophyllineCYP1A2case report1 (na)Adult healthy volunteer (Canada)nandDoubled t1/2 during acute viral infectionna([@bb0165])  Anti-malaria drugsquinineCYP3A4prospective study (PK analysis)5 (na)Adults with experimentally-induced malaria (USA)nabody temperature: 38.1± 0.2 °CIncreased exposure during experimentally-induced malariaSymptoms of cinchonism during malaria([@bb0495]; [@bb0725])quinineCYP3A4prospective study (PK analysis)73 (na) (51 infected patients and 22 controls)Children with uncomplicated malaria\
(na)nanaReduced CL, Vd during malaria and increased exposure during uncomplicated malaria episodeNo adverse effect was recorded([@bb0495]; [@bb0630])quinineCYP3A4prospective comparative study (PK analysis)38 (na) (25 cerebral malaria and 13 uncomplicated malaria)Adults and children with malaria (Thailand)nanaReduced CL, Vd during malaria (especially in cerebral malaria) compared to convalescence periodNo adverse effect was recorded([@bb0495]; [@bb0780])quinineCYP3A4prospective comparative study (PK analysis)15 (na)Adults with malaria (Thailand)less than 7 daysbody temperature: 38.4 ±1.2°C\
Parasitemia: 58100 \[18600-183000\] parasites/μLDecreased CL and increased exposure during malaria episode compared to convalescence periodna([@bb0495]; [@bb0705])quinineCYP3A4prospective study (PK analysis)16 (na)Adult patients with severe or moderately severe malaria (Thailand)nabody temperature: 38.4 \[range: 37.0-40.1\] °C\
parasitemia: 15054\
\[range: 44-346222\] parasites/μLReduced Cl, Vd during malaria episode compared to convalescence periodna([@bb0495]; [@bb0580])quinineCYP3A4prospective study (PK analysis)6 (na)Adults and children with uncomplicated malaria (Nigeria)nabody temperature: 38.6 ± 0.6°C\
parasitemia: 33064\
\[range: 11250-58999\] parasites/μLReduced CL, Vd and increased exposure during malaria episode compared to convalescence periodNo adverse effect was recorded([@bb0030]; [@bb0495])quinineCYP3A4prospective study (PK analysis)22 (na)Pregnant women (2^nd^ and 3^rd^ trimester)\
(Uganda)nabody temperature: 37.2 \[36.0-38.9\] °C\
parasitemia: 2240 \[39.0-44.5\] parasites/μLBody temperature and parasitemia identified as covariates affecting CL and bioavailability, respectivelyNo adverse effect was recorded([@bb0345]; [@bb0495])  Anti-viral drugslopinavirCYP3A4retrospective observational study8 (8)COVID-19 adult patientsndCRP range: 1.6 to 184.7 mg/LCorrelation between Cmin and CRPna([@bb0660])lopinavirCYP3A4retrospective observational study12 (30)COVID-19 adult patientsndCRP range: 19.4 to\
157.5 mg/LHigh bound and unbound Cmin in COVID-19 patients compared to HIV patientsDiarrhea (n=6), nausea/vomiting (n=2)([@bb0220])[^5][^6][^7]

4.1. Psychotropic drugs (see [Table 3](#t0015){ref-type="table"}) {#s0045}
-----------------------------------------------------------------

Numerous studies have highlighted the impact of inflammation on clozapine metabolism. Several case reports have described elevated concentrations of clozapine in patients experiencing acute inflammatory episodes associated with clinical signs of intoxication ([@bb0390]; [@bb0235]; [@bb0280]). However, an increase in the clozapine and norclozapine trough concentration (Cmin) and clozapine concentration/dose ratio (C/D) was observed in two patients, without symptoms of intoxication ([@bb0625]). This link between the inflammatory status and clozapine pharmacokinetics was later confirmed by retrospective comparative studies using CRP levels as a marker of inflammation. Several studies on retrospective TDM data have reported an impact of abnormal CRP values on the clozapine concentration and C/D and a decrease in the metabolic clozapine/norclozapine ratio ([@bb0255]; [@bb0565]). Unfortunately, safety data were not available in these studies.

Little data are available for other antipsychotic drugs. An impact of inflammation on the pharmacokinetics of risperidone was described in two clinical cases (Hefner et al., 2015a) and confirmed in a retrospective comparative study. An increase in the C/D of the risperidone active moiety has been observed in patients with CRP \> 5 mg/L ([@bb0255]). However, the impact on the pharmacokinetics appears to be lower for risperidone than clozapine (increase in the C/D of 24.2 *vs* 48.0%). Although safety data were also lacking for risperidone, the clinical impact should be minimal. By contrast, no impact of the CRP value was observed on the pharmacokinetics of quetiapine in the same study. Concerning antidepressant drugs, one retrospective comparative study showed that the CRP concentration was not associated with the pharmacokinetics of citalopram or venlafaxine ([@bb0250]; [@bb0270]). These results confirm a different impact of inflammation on psychotropic drug metabolism depending on the CYP isoform and their respective contribution in the drug clearance. Given that other psychotropic drugs are highly metabolized, an impact of inflammation would be expected for many. However, only scant data are available to support this hypothesis and further studies are needed, including comparative clinical trials.

4.2. Other central nervous system drugs (see [Table 3](#t0015){ref-type="table"}) {#s0050}
---------------------------------------------------------------------------------

There is only limited information on the impact of inflammation on the pharmacokinetics of antiepileptics and sedative drugs.

In a recent retrospective comparative study, an increase of the C/D of perampanel was observed in epileptic patients with CRP \>15 mg/L ([@bb0805]). In a case report on an eight-year-old girl, for whom clobazam (also mainly metabolized by CYP3A4) was co-administered, no impact on the clobazam C/D ratio was observed ([@bb0805]). By contrast, an increase in the metabolism and plasma clearance of valproic acid and phenytoin has been observed in traumatic brain injury patients ([@bb0015]; [@bb0445]). The authors hypothesized that increased clearance of these drugs could be explained by changes in both pro- and anti-inflammatory factors in this population.

The impact of inflammation on the pharmacokinetics of midazolam was studied using population pharmacokinetics models on critically ill adult and pediatric populations. A first model was developed based on 26 critically ill Dutch children for whom a decrease in the clearance of midazolam correlated with disease severity but not CRP levels or leucocyte counts ([@bb0765]). In 2016, a model developed on a larger cohort (83 patients and 523 concentration data points) demonstrated that midazolam clearance was associated with CRP concentration and organ failure but not with IL-6 or

TNF-α concentrations ([@bb0760]). The impact of inflammation on the pharmacokinetics of midazolam has also been observed in other populations (full-term neonates and critically ill and healthy adult populations) but not in preterm neonates ([@bb0055]; [@bb0170]). These heterogeneous results highlight the multifactorial aspect of the pharmacokinetic variability of critically ill patients, inflammation likely being one among many factors. Further studies are required, including safety data, to better describe the influence of inflammation on antiepileptic and sedative drug metabolism.

4.3. Immunosuppressive drugs (see [Table 3](#t0015){ref-type="table"}) {#s0055}
----------------------------------------------------------------------

In a study of 13 kidney transplant patients with a urinary tract infection, the concentrations of tacrolimus were higher during treatment with ertapenem than those measured before the infection. Although no biomarkers of inflammation were presented in this study, it can be hypothesized that the increased exposure to tacrolimus may have been related to the episode of acute infection that required antibiotic treatment ([@bb0045]). Consistent with this hypothesis, the Cmin, AUC 0-4 h, Tmax, and Cmax of tacrolimus were reported to be significantly higher during episodes of diarrhea in kidney transplant patients and the Cmin of tacrolimus returned to its previous concentration 2 to 4 weeks later ([@bb0650]).

In a meta-analysis that included 66 population pharmacokinetic studies, CRP levels had no significant effect on the interpatient variability of tacrolimus pharmacokinetics, in contrast to CYP3A5 genotypes ([@bb0065]). However, CRP was investigated in less than 10% of the studies.

The tacrolimus Cmin and dose-normalized pharmacokinetic profile were higher for 11 renal transplant recipients experiencing an episode of infectious diarrhea than for nine renal transplant recipients without diarrhea. Intestinal glycoprotein P activity was decreased by approximately 50% in the patients with diarrhea, suggesting that persistent and severe diarrhea was associated with increased oral bioavailability of tacrolimus. In two cases of pediatric liver transplantation patients treated with either tacrolimus or cyclosporine, the blood concentration of these immunosuppressants nearly doubled 24 hours after an episode of diarrhea with fever. Following the remission of diarrhea, the cyclosporine Cmin returned to the concentrations observed before the diarrheal episode ([@bb0410]).

The Cmax of cyclosporine correlated to those of IL-6 and CRP in six patients who received bone marrow transplants ([@bb0100]). Moreover, the CYP P450-mediated formation of cyclosporine metabolites decreased with inflammation until it was below the limit of detection ([@bb0100]).

In a prospective PK study, two children with acute lymphoid leukemia had unexpected elevated sirolimus concentrations after experiencing flu-like symptoms, such as fever and cough, for three days ([@bb0470]). The estimated clearance of sirolimus decreased by approximately 40% and 50% for the two patients, necessitating a dose reduction. A similar result was observed in a sirolimus PK study in patients with vascular anomalies ([@bb0465]). In patients with documented infection, sirolimus clearance dropped by approximately 50%, requiring a dose reduction.

Finally, in renal transplant patients, a higher mycophenolic acid (MPA) AUC 0-9 h ([@bb0555]) or AUC 0-12 h was observed in patients with infectious disease than in those without ([@bb0690]).

4.4. Antifungal drugs (see [Table 3](#t0015){ref-type="table"}) {#s0060}
---------------------------------------------------------------

A first retrospective study conducted on 128 patients reported a significantly elevated voriconazole Cmin in patients with moderate or severe inflammation (defined by CRP levels between 41-200 mg/L and \> 200 mg/L, respectively). This association remained significant after adjustment for multiple covariables (gender, age, dose, route of administration, liver enzymes, and comedications) ([@bb0740]). Such a link between inflammatory status (assessed most often by CRP levels) and voriconazole pharmacokinetics was later confirmed in numerous retrospective cohorts ([@bb0145]; [@bb0150]; [@bb0195]; [@bb0415]; [@bb0505]; [@bb0530]; [@bb0745]; [@bb0770]; [@bb0820]) and in one prospective mono-center study ([@bb0755]). Moreover, several cases reporting a similar evolution of voriconazole Cmin and CRP levels during longitudinal follow-up illustrate the impact of acute inflammation on voriconazole exposure at the individual level ([@bb0730]; [@bb0740]; [@bb0745]; [@bb0820]). Although these studies were heterogeneous in terms of study population (solid organ transplants and hematological patients), biological markers of inflammation (CRP, IL-6, IL-18 levels), and voriconazole pharmacokinetic parameters (Cmin, metabolic ratio), most reported increased voriconazole exposure during acute inflammation (see [Table 3](#t0015){ref-type="table"}). Only one study with a limited sample size, performed on 11 children \< 12 years of age, did not show any impact of inflammation on voriconazole exposure ([@bb0025]).

Several authors have proposed models to predict the increase in the voriconazole Cmin in response to inflammation ([@bb0150]; [@bb0195]; [@bb0740]; [@bb0745]; [@bb0755]). As only a limited number of patients were included in several studies ([@bb0150]; [@bb0195] [@bb0755]), these models need to be validated in larger independent studies simultaneously investigating inflammatory status and pharmacogenetics. This is particularly important, as two studies have suggested that the impact of inflammation on the voriconazole Cmin depends on the CYP genotype ([@bb0195]; [@bb0755]). Moreover, severe inflammation may blunt the influence of pharmacogenomic markers (CYP2C19 phenotype or a combined genetic score integrating the CYP2C19 and CYP3A genotypes) on voriconazole exposure, as a case-control study identified severe inflammation (defined by a CRP \> 96 mg/L) as the unique risk factor of voriconazole overdose, whereas pharmacogenetic markers did not have a significant impact in this study ([@bb0200]).

There is little data concerning other triazole antifungals. One prospective study conducted on 55 patients treated with posaconazole did not find any association between the posaconazole Cmin and inflammation, assessed by CRP levels ([@bb0430]). Similarly, itraconazole exposure did not appear to be related to inflammation, since the unique retrospective cohort published to date did not find any link between the itraconazole Cmin and CRP levels ([@bb0505]).

4.5. Other drugs (see [Table 3](#t0015){ref-type="table"}) {#s0065}
----------------------------------------------------------

The results of additional studies also support the hypothesis of the inhibition of DMETs during acute infection. For example, increased concentrations of theophylline during acute viral illness ([@bb0090]; [@bb0165]; [@bb0325]; [@bb0350]; [@bb0800]) and of quinine in the early phases of malaria treatment (see review ([@bb0495])) have been reported. Very recently, two short reports described higher plasma concentrations of lopinavir in severe COVID-19 patients ([@bb0220]; [@bb0660]) compared to those observed in HIV-infected patients and in relation to plasma CRP concentrations ([@bb0660]).

5. Pharmacological consequences of inflammation-induced metabolic phenoconversion in patients with chronic inflammation {#s0070}
=======================================================================================================================

As for acute inflammation, an inhibitory effect of chronic inflammation on DMETs is expected. However, the contribution of inflammation in the variability of drug exposure is difficult to address in patients with chronic disease due to numerous confounders, such as chronic infection, ageing, physical inactivity, stress, or disturbed sleep, which may be associated with some chronic diseases ([@bb0185]) and polymedication.

5.1. HIV infection {#s0075}
------------------

Despite effective antiretroviral therapy, chronic and persistent inflammation is observed in HIV-infected patients. Inflammation-induced pharmacokinetic variability may thus have a significant clinical impact on antiretroviral therapy medication, as efficacy and toxicity are directly associated with drug exposure. Indeed, higher inflammatory biomarker concentrations have been described in HIV patients than uninfected adults and inflammation persists after the suppression of HIV-RNA by antiretroviral therapy ([@bb0525]). Interestingly, a recent study showed that the level of inflammatory markers varies with the level of adherence ([@bb0075]).

CYP activity in HIV-infected patients has been assessed using phenotyping tests. Lower CYP3A4, CYP2D6, and N-acetyl transferase 2 activity (18%, 90%, and 53%, respectively) was observed in 17 HIV-infected adults relative to that in uninfected controls using caffeine, dextromethorphan, and midazolam tests ([@bb0290]). Conversely, no significant difference was found in CYP1A2 activity. In another study using midazolam, dextromethorphan, and digoxin as *in vivo* phenotyping tests, overall CYP3A activity was approximately 50% lower in HIV-infected patients than in healthy volunteers (30 *vs* 12 patients, respectively), whereas CYP2D6 activity was unchanged ([@bb0285]).

An impact of inflammation on the pharmacokinetics of antiretrovirals mainly metabolized by CYP3A, would thus be expected. However, data in the literature are sparse. Decreased maraviroc and elvitegravir clearance has been observed according to inflammatory status ([@bb0665]). Co-administration of IL-2 with indinavir to nine HIV patients led to an 88% increase in the AUC of indinavir ([@bb0570]). Conversely, no significant correlation was observed between atazanavir clearance and inflammation biomarker concentrations in 107 HIV patients ([@bb0750]). Yet, in this later study, the effect of inflammation could have been blunted by the presence of the booster ritonavir, which is systematically associated with atazanavir to decrease its clearance. Further studies are thus required to better define the impact of inflammation on the pharmacokinetics, tolerance, and efficacy of antiretroviral treatment.

The inflammatory status of HIV-infected patients may also have an impact on the pharmacokinetics of non-antiretroviral drugs. However, no clinical data are currently available and the potential impact is yet to be investigated.

5.2. Metabolic disorders {#s0080}
------------------------

Few studies are available for patients with metabolic disorders, but CYP-mediated drug clearance is likely to be reduced in type 2 diabetes. Studies performed on liver tissue from diabetic patients demonstrated a decrease in total CYP content ([@bb0695]), with diminished expression and activity of CYP3A relative to controls ([@bb0140]). In addition, the exposure of the CYP3A substrate nisoldipine is elevated in hypertensive diabetic patients ([@bb0425]) and cyclosporine metabolite concentrations are lower in kidney transplant recipients with diabetes mellitus ([@bb0010]) than in controls. Although these data are concordant, the role of inflammation in such CYP downregulation in diabetes has never been investigated. Recently, a prospective study using a cocktail of probe drugs showed a decrease of approximately 38, 46, and 45% of the mean metabolic activity for CYP3A, 2C19, and 2B6, respectively, in 38 patients with type 2 diabetes relative to 35 controls ([@bb0215]). Considering all diabetic and non-diabetic subjects, the IL-6 concentration significantly negatively correlated with the activities of CYP2B6, 2C19, and 3A in univariate analysis. Moreover, IFN-γ and TNF-α concentrations were identified as independent determinants of CYP2C19 and 2B6 activity ([@bb0215]). These data all suggest that the inhibition of CYP-mediated drug clearance in type 2 diabetes may be related to inflammatory processes. However, these findings must to be confirmed, as the controls of these studies were often not well matched in terms of age, sex, or body mass index ([@bb0010]; [@bb0215]; [@bb0425]).

Nonalcoholic fatty-liver disease (NAFLD) is associated with alterations of DMET expression and activity in experimental murine models and patients (see review ([@bb0105])). This translates into increased midazolam exposure and an increased AUC of the glucuronide metabolites of morphine and acetaminophen via the upregulation of the MRP3 efflux transporter. However, these results are limited and sometimes conflicting and need to be further investigated.

5.3. Chronic kidney disease (CKD) {#s0085}
---------------------------------

The principal consequence of CKD on drug pharmacokinetics is a decrease in renal clearance. However, an impact of CKD on non-renal clearance has also been observed in many studies. Decreased CYP2C11, 3A1, 3A2, and N-acetyl transferase activity has been observed in non-clinical studies, whereas no modification was observed in CYP 1A1, 2B1, 2C6, and UDP-GT activity ([@bb0515]). In clinical studies, decreased non-renal clearance has been observed for numerous drug substrates of metabolizing enzymes ([@bb0535]). Uremic factors (such as parathyroid hormone) that accumulate in end stage renal disease were identified as the main factors that contribute to varying non-renal clearance. Indeed, uremic factors decrease the mRNA expression and thus activity of drug-metabolism enzymes ([@bb0515]). As a systemic inflammatory response is observed in CKD patients ([@bb0700]), inflammatory factors may also be involved in reduced CYP activity. However, data are still lacking to accurately describe the impact of each factor in this multifactorial change. The impact of inflammation on CKD patients has been independently investigated in only one study, using alprazolam as a probe drug for CYP3A4 activity ([@bb0475]). The ratio of alprazolam to 4-hydroxyalprazolam correlated with CRP concentrations in 26 hemodialysis patients, suggesting the downregulation of CYP3A4 activity by inflammation.

5.4. Cancer {#s0090}
-----------

CRP concentrations positively correlate with weight loss, anorexia-cachexia syndrome, extent of disease, and recurrence in advanced cancer ([@bb0420]). Rivory *et al.* evaluated hepatic CYP3A activity using the phenotypic ^14^C-erythromycin breath test in cancer patients with CRP \> 10 mg/L. They showed a mean 30% decrease in CYP3A activity relative to that in patients without an acute-phase response ([@bb0615]). In patients with advanced cancer, docetaxel pharmacokinetics were the only predictive factor for hematological toxicity. The odds of severe hematological toxicity were approximately nine-fold higher for patients with reduced docetaxel clearance. The odds of non-hematological toxicity were approximately three-fold higher for patients with elevated orosomucoid or CRP concentrations (\> 1.5 g/L and \> 10 mg/L, respectively) ([@bb0095]).

5.5. Autoimmune inflammatory diseases {#s0095}
-------------------------------------

Studies performed in patients with rheumatoid arthritis or Crohn's disease support the hypothesis that inflammation contributes to the inhibition of drug metabolism. For example, higher exposure of verapamil in patients suffering from rheumatoid arthritis ([@bb0440]) or Crohn's disease ([@bb0645]) than controls has been reported. In addition, rheumatoid arthritis patients exhibit higher plasma concentrations of simvastatin, another CYP450 substrate ([@bb0655]) and lower plasma concentrations of 4-ßhydroxycholesterol, an endogenous CYP3A4 metabolite ([@bb0785]). CYP3A4 activity has been shown to correlate with proinflammatory cytokine levels, especially those of IL-1ra, IL-6, and CXCL8 ([@bb0790]). In addition, the central role of IL-6 in the inhibition of CYP clearance in rheumatoid arthritis has been shown in clinical trials evaluating monoclonal antibodies targeting IL-6 ([@bb0375]; [@bb0655]; [@bb0845]). Indeed, these studies all showed that pharmacological inhibition of IL-6 restored CYP3A activity, with a significant decrease in simvastatin exposure of approximately 55 and 57% after the administration of sarilumab ([@bb0380]) or tocilizumab ([@bb0655]), respectively. Conversely, several other biotherapies targeting proinflammatory cytokines, such as TNF-ɑ ([@bb0120]; [@bb0180]), IL-17 ([@bb0050]), or IL-23 ([@bb0320]; [@bb0330]) did not influence CYP activity. However, any effect of such biologics needs to be verified for various diseases with varying levels of proinflammatory cytokines, as the magnitude of these disease-dependent drug interactions are *per se* affected by the underlying disease.

5.6. Liver disease and liver transplant {#s0100}
---------------------------------------

In chronic liver disease, most studies have focused on the impact of liver impairment on pharmacokinetics and inflammation is thus difficult to investigate as an independent factor of pharmacokinetic variability. UDP-GT mRNA levels were compared between liver biopsies of patients with low and high fibrosis or inflammation scores. Lower hepatic UDP-GT mRNA levels were observed in biopsies from patients with a high inflammation score, but not in those from patients with a high degree of fibrosis ([@bb0110]). Some clinical data are available on chronic hepatitis C and B infections, in which chronic and persistent inflammation can be observed, such as in HIV infection. Morcos *et al.* investigated the impact of hepatitis C infection in chronically infected patients without liver impairment using midazolam as *in vivo* probe substrate. The midazolam metabolic ratio was lower in treatment-naïve patients (n = 35) and interferon null-responders (n = 24) than in healthy volunteers (n = 107), suggesting lower CYP3A4 activity in chronic hepatitis C patients ([@bb0480]). In another study, lidocaine and its metabolite monoethylglycinexylidide (MEGX) were used as probe substrates of CYP activity in hepatitis C virus-positive cirrhotic patients with *Helicobacter pylori* gastric infection ([@bb0210]). The mean MEGX concentrations were significantly lower in *Helicobacter pylori* infected than non-infected patients, independently of the Child-Pugh classification. These results suggest an impact of infection-induced inflammation on lidocaine metabolism. Unfortunately, data on the inflammatory factor concentrations were not available for these two studies. A decrease of 68% in CYP1A activity was also observed in 41 chronic hepatitis B patients ([@bb0775]).

Inflammation is observed during liver regeneration in living-donor liver transplantation and could affect drug metabolism in both donors and recipients ([@bb0395]). However, no data are currently available to confirm this hypothesis.

6. How to integrate the inflammatory status in personalized medicine? {#s0105}
=====================================================================

Inflammation reduces clearance by certain CYP and phase 2 enzymes, translating into the phenoconversion of intra-individual metabolic capacities. In particular, phenoconversion for extensive-metabolizer patients results in the change of a genotypic extensive metabolizer into a phenotypic poor metabolizer, leading to genotype-phenotype mismatches and an unpredictable increase in pharmacokinetic exposure to drugs that are DMET substrates, a drastic decrease in pharmacokinetic exposure to the corresponding metabolites, or reduced activity of pro-drugs. The clinical significance in terms of efficacy and safety of phenoconversion depends on whether the drug and/or its metabolites support the pharmacodynamic activity and their therapeutic index. In addition to extrinsic factors, including drug-drug interactions (see previous review ([@bb0675])) or food/drug interactions, inflammation is an important intrinsic factor that can cause metabolic phenoconversion. Thus, unlike genotype, the pharmacokinetic phenotype of a subject is dynamic and inflammation-induced phenoconversion can transitorily blunt the pharmacogenotype.

*Opinion: With the exception of pharmacogenotypes that contraindicate the use of certain drugs (HLA-B\*5701 for abacavir, TPMT for azathioprine), genotype-guided dosing should be tempered by the inflammatory status of the patient. In hematological patients for example, severe inflammation has been shown to be the only independent predictor of voriconazole overexposure, whereas pharmacogenetic biomarkers had no significant impact* ([@bb0200]). *When interpreting a pharmacogenotype, pharmacologists should alert clinicians that severe inflammation can transitorily blunt a DMET genotype and the dose adjustment should account for the inflammatory status of the patient.*

Experimental and clinical studies have showed that the impact of inflammation depends on different CYP isoforms (see [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). Most data agree to suggest that inflammation is associated with inhibition of CYP1A, CYP3A, CYP2C9 and CYP2C19, which results in increased exposure of their respective substrates. Several studies have shown that plasma CRP concentrations mirror CYP substrate concentrations, such as those of voriconazole ([@bb0150]) and tacrolimus ([@bb0040]). Others have reported an association between high CRP levels and overexposure to voriconazole ([@bb0200]), clozapine ([@bb0565]), or risperidone ([@bb0255]). For voriconazole, the CRP concentration is an independent predictor of the voriconazole Cmin ([@bb0195]) and the voriconazole Cmin correlates with the CRP level ([@bb0150]; [@bb0505]; [@bb0740]). In most studies, metabolic phenoconversion-induced drug overexposure occurred mainly in the presence of severe inflammation (CRP \> 96 mg/l for voriconazole ([@bb0200]), CRP = 300 mg/l for midazolam ([@bb0765])), CRP = 19.4 to 157.5 mg/l for lopinavir ([@bb0220])).

The impact of inflammation is less evident on CYP2D6. Limited or heterogeneous effects of inflammation on the regulation of CYP2D6 have been reported in experimental animal models (Chaluvadi et al., 2009; [@bb0130]; [@bb0230]; [@bb0540]) and discordant results regarding the activity of CYP2D6 have been observed in HIV-infected patients ([@bb0285]; [@bb0290]). Moreover, in patients with psychiatric disorders, risperidone exposure (which is metabolized through CYP2D6) was increased in case of inflammation, while venlafaxine, another CYP2D6 substrate was not ([@bb0255]). These clinical data are also consistent with the great interindividual variability of the metabolism mediated by CYP2D6 due to genetic polymorphisms.

A small number of clinical studies have suggested an inhibitory effect of inflammation on UDP-GT activity. Higher exposure to MPA was observed in renal transplant patients with infectious disease than in patients without ([@bb0555]). Conversely, the pharmacokinetics of the UDG-GT substrate posaconazole was not influenced by the inflammatory status. These data suggest that, the effect of inflammation may vary according to the UDP-GT subfamily, as for CYP.

Lastly, the impact of inflammation on drug exposure may also depend on the importance of drug metabolism in the total clearance of the drug, the contribution of CYP or UDP-GT family members in this metabolism, and their genetically-determined basal activities. The different effect of inflammation on MPA and posaconazole metabolism could for example be explained by the fact that 90 to 99% of the dose of MPA is metabolized by UDP-GT1A9 ([@bb0060]), whereas only 15 à 17% of the dose of posaconazole is metabolized by UDP-GT1A4 ([@bb0355]).

*Opinion: The impact of inflammation on drug exposure differs according to the drugs and TDM could help to measure pharmacokinetic variability. In parallel to TDM, monitoring CRP concentrations or checking for fever may be helpful to explain the occurrence of systemic overexposure of drugs metabolized by CYP1A2 (clozapine, theophylline), CYP3A (voriconazole, tacrolimus, everolimus, ciclosporin, midazolam, perampenel, quinine, lopinavir) or type 2 enzymes (mycophenolic acid) when a drug/drug interaction with an inhibitor can be ruled out.*

*Concerning the transcriptional inhibitory effect of inflammation on DMETs, an increase in plasma CRP concentrations may precede an increase in CYP substrate plasma/blood concentration. The increase of this routine biomarker of inflammation should alert pharmacologists and clinicians to the increased risk of overdose of DMET substrates with a short elimination half-life. Clinical care and TDM should be reinforced in this context.*

The clinical consequences of inflammation-induced metabolic conversion are heterogenous. Overexposure to theophylline or clozapine in association with acute inflammatory episodes has been associated with concomitant clinical signs of drug-related toxicity, whereas the immediate clinical consequences of increased exposure to voriconazole, tacrolimus, or risperidone associated with inflammation have not been documented (see [Table 3](#t0015){ref-type="table"}). These data confirm that the inhibitory effect of inflammation on CYP may vary according to the CYP subfamily as previously discussed. *In vitro* hepatocyte experiments have shown that the potency of IL-6 to inhibit CYP was the strongest towards CYP1A2 relative to other CYPs ([@bb0135]). Since theophylline and clozapine are CYP1A2 substrates, the particular potency of IL-6 to inhibit CYP1A2 could explain the onset of theophylline or clozapine toxicity during acute episodes of inflammation.

Although the metabolic phenoconversion induced by inflammation may not be associated with short-term clinical signs of toxicity for other drugs (tacrolimus, voriconazole, risperidone), acute inflammation can also contribute to the increase in intra-individual variability of drugs that are CYP substrates, possibly leading to deleterious long-term consequences. For example, increased intra-individual variability of the tacrolimus blood Cmin is associated with a poorer clinical outcome in hepatic transplant patients ([@bb0590]). Moreover, it should also be kept in mind that total plasma drug concentration (free concentration + bound concentration) are measured during TDM or in most clinical studies (see [Table 3](#t0015){ref-type="table"}). Certain drugs have strong binding affinity (\>98%) for orosomucoid, the concentration of which is increased during acute inflammation (see [Table 1](#t0005){ref-type="table"}). Thus, in a context of severe inflammation, the increased plasma total concentration of a drug highly bound to orosomucoid mainly reflects increased bound concentration. For example, correlations between orosomucoid concentration and risperidone+9-OH risperidone or lopinavir exposures have been described in a schizophrenic patient with pneumonia ([@bb0260]) or in patients with severe HIV disease respectively ([@bb0550]). Since the bound concentration of a drug do not supports its pharmacological activity, this could contribute to explain the absence of clinical signs of toxicity in some situations, although a total overexposure is measured ([@bb0260]).

*Opinion: When overexposure to a drug that is a DMET substrate with a narrow therapeutic index occurs in the context of acute infection, a treatment adaptation of this drug should not be systematically recommended. Pharmacologists should also take into consideration the pharmacokinetic properties of the drug, including its binding to orosomucoid, the importance of the different metabolic pathways involved in its clearance, and its terminal elimination half-life. For drugs highly bound to plasma proteins, a dose reduction could sometimes lead to loss of efficacy. But if adverse effects are observed, pharmacologists can suggest the brief discontinuation of treatment rather than dose reduction to avoid secondary underexposure upon the resolution of inflammation.*

The resolution of an acute inflammatory episode is a complex physiological process, depending on the trigger of inflammation, and no study has investigated the duration of its resolution. This lack of data is a strong limitation for proposing dose reduction of DMET substrates to avoid consequent pharmacokinetic underexposure, notably for drugs with a narrow therapeutic window.

*Opinion. As no studies have investigated the duration of the metabolic phenoconversion induced by inflammation, the combination of TDM and CRP monitoring may be useful to prevent drug underexposure when the inflammation episode is resolved.*

Several case reports have suggested the repression of DMET inhibition at the resolution of the inflammatory episode, leading to reduced exposure of the DMET substrate in the context of chronic inflammation. The tacrolimus blood concentration decreased in two HCV-infected and liver-transplanted patients during treatment with daclastavir/sofosbuvir/ribavirin ([@bb0685]). Since a direct drug/drug interaction between the direct-acting antivirals, ribavirin and tacrolimus, could be excluded, this study suggested that the unexpected observed decrease in the tacrolimus blood concentration when the sustained virological response was achieved could have been the consequence of the resolution of the HCV infection ([@bb0685]).

*Opinion. A potential impact of inflammation needs to be considered when unexpected variations in the blood concentrations of a DMET substrate occur in the absence of direct drug/drug interactions.*

Treatment of rheumatoid arthritis patients with the monoclonal antihuman IL-6 receptor antibody tocilizumab ([@bb0655]) or sarilumab ([@bb0375]) normalized plasma CRP levels within one week after infusion and reduced simvastatin plasma exposure by 43 and 54%, respectively. These data suggest that blockade of the IL-6-dependent pathway reversed the suppression of CYP3A4 activity induced by inflammation and confirm the key role of IL-6 in the downregulation of CYP activity. Conversely, the antihuman IL-17A monoclonal antibody sekukinumab failed to modify the pharmacokinetic profile of midazolam in patients with moderate to severe psoriasis ([@bb0050]). Similarly, the antihuman IL-23 antibody risankizumab did not affect the *in vivo* activity of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A in patients with moderate plaque psoriasis ([@bb0330]). However, systemic inflammation was minimal in these study populations.

*Opinion. In patients with severe chronic systemic inflammation, treatment with IL-6 monoclonal antibody (tocilizumab or sarilumab) reverses the suppression of CYP activity induced by inflammation. This requires intensification of clinical laboratory monitoring of DMET substrate drugs over the first week of treatment at least and, if underexposure is detected, increasing the dose so as to avoid loss of efficacy.*

The impact of chronic or acute inflammation on drug pharmacokinetics has been studied using population pharmacokinetic models in only a few studies including inflammation factors as covariates. However, this methodology is probably a good approach to evaluate the impact of inflammation on pharmacokinetics and metabolism as an independent factor of variability. As previously described, inflammation is one of the many factors (demographic, genetic, pathological, etc.) that influences drug pharmacokinetics. Pharmacokinetic population studies could allow identification of the contribution of inflammation in interindividual variability relative to that of other covariates, such as disease severity or glomerular filtration rate. Studying the relationship between inflammation and drug pharmacokinetics could also be helpful in adapting treatment, taking into account the limitation of the large intra-individual variability observed due to the inflammation status.

*Opinion: Inflammation biomarkers (such as CRP) must be included in population pharmacokinetic studies as potential covariates, like renal or hepatic function biomarkers, especially for highly metabolized drugs.*

7. Conclusion {#s0110}
=============

Compelling evidence suggests that inflammation is a major regulator of DMETs and thereby contributes to intra- and interindividual pharmacokinetic variability of DMET substrates. The inhibitory effect of inflammation likely depends on its severity and the contribution of DMETs in the intrinsic clearance of a drug. However, the concentrations of the inflammatory biomarkers that inhibit the activity of each DMET are yet to be determined. This is essential in preventing overexposure to drugs that are DMET substrates, particularly concerning the ageing population and patients with a high prevalence of inflammatory comorbidities, including acute infections, and requires further studies. Studies aiming to investigate the genotype-predicted phenotype should also take into account the inflammatory status of patients to avoid misinterpretation, as the phenoconversion induced by inflammation may blunt the impact of genetic polymorphisms on drug pharmacokinetics and responses. As for genotype, demographic data, drug-drug interactions, and inflammatory biomarkers should be systematically taken into consideration for the personalization of drug treatment.
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[^2]: IFNβ: beta interferon, IFN*γ*: gamma interferon, IL: interleukin, MIP-1α: macrophage inflammatory protein 1α, MCP-1: monocyte chemoattractant protein-1, KC: chemokine CXCL1, mRNA: m**essenger ribonucleic acid, RANTES: chemokine CCL5, SAA, serum amyloid A,** TNFα: tumor necrosis factor alpha, **-**: not determined, +/- according to the considered isoenzymes.

[^3]: List of publications indicated in this table is not exhaustive. For example, **because studies investigating the impact of diabetes on various animal models were recently reviewed** ([@bb0795])**, this table does not include the works discussed in that review, except those which were published after its publication.**

[^4]: According to [@bb0815], human CYP2C9 and CYP2C19 corresponds to CYP2C11 and CYP2C22 in rats.

[^5]: AM: cyclosporine metabolites, C/D: concentration/dose ratio, Cmin: trough concentrations, CL: clearance, Cmin: trough concentration, CRP: C reactive protein, CYP: cytochrome, FMO: flavin-monooxygenase 3, na: not available, nd: not determined, IL-6: interleukin 6, Pgp: glycoprotein P, PK: pharmacokinetics, MPE: median predicted error, t1/2: elimination half-life, SOT: solid organ transplant, Tmax: time after dose to maximum concentration, TNFα: tumor necrosis factor α, Vd: volume of distribution.

[^6]: Data are indicated as mean (interval confidence or SD) or median \[25th-75th percentile or range\].

[^7]: \*Clozapine therapeutic reference range: 350-600 ng/mL ([@bb0270]); \*\* Voriconazole therapeutic reference range : 1-4 mg/L.
